Risk of arrhythmias in 52 755 long-distance cross-country skiers: a cohort study
Jan 02, 2014
Overview:Background and objectives: It has been hypothesised that athlete’s heart, secondary to long term endurance sport practice, may increase the incidence of arrhythmias, particularly atrial fibrillation (AF), atrial flutter, sinus node dysfunction, and eventually right ventricular tachycardia. Several mechanisms have... more
More research needed to address the relationship between inflammation and CVD risk
Feb 25, 2019
Overview: Alberto Lorenzatti, MD, FACC* Even after optimal pharmacotherapy and precise revascularizations, the recurrence of myocardial infarction remains at approximately one-third for the 5 year-period after an acute coronary syndrome.1,2 The recognition, in the past few decades, of the... more
Enterococcus faecalis Infective Endocarditis: A Pilot Study of the Relationship Between Duration of Gentamicin Treatment and Outcome
Jul 04, 2013
Overview:Background International guidelines on IE2,3 recommend 4–6 weeks of penicillin or ampicillin plus an aminoglycoside for treating β-lactam– and gentamicin-susceptible enterococcal IE. However, the results of previous studies2 led to a change in the Danish Society of Cardiology guidelines in... more
The effect of the REGN727 anti-PCSK9 monoclonal antibody on LDL cholesterol
May 02, 2012
Overview:Background Proprotein convertase subtilisin kexin type 9 (PCSK9) is a circulating protein that binds to Low Density Lipoprotein LDL Receptors (LDLR), leading to their accelerated degradation, impairing LDL clearance and increasing LDL cholesterol levels. PCSK9 is mainly of hepatic origin,... more
Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in UK patients with atrial fibrillation
May 17, 2012
Overview:Background Atrial fibrillation (AF) is the most common sustained cardiac arrhythmia, occurring in 1–2% of the general population. The main goal of AF treatment is to avoid thromboembolic events (fivefold increased risk compared with those in sinus rhythm) by instituting... more
Multaq (dronedarone): Drug Safety Communication
Apr 28, 2017
Overview:By Professor Juan Tamargo, Madrid, Spain The U.S. Food and Drug Administration (FDA) has completed a safety review of the drug Multaq (dronedarone). Data from two clinical trials, PALLAS and ATHENA, showed that Multaq increased the risk of serious cardiovascular... more
Guidelines for the Prevention of Stroke in Women. A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association
Mar 24, 2014
Overview:Stroke is the third leading cause of death in several industrial countries and occurs in the general context of atherosclerosis. Conventional (sex, age, heredity, dyslipidemia, diabetes mellitus, hypertension, sedentary lifestyle, smoking, and endothelial dysfunction) and non conventional (elevated levels of... more
Changes in HDL cholesterol and cardiovascular outcomes after lipid modification therapy
Jun 18, 2012
Overview:In the present study the authors aimed to replicate the earlier observation from the Framingham Offspring Study that changes in HDL-C associated with lipid modification therapy are associated with a lower risk of cardiovascular events independent of changes in LDL-C... more
Novel lipid lowering therapy against coronary atherosclerosis: role of PCSK9 inhibitors
Jul 25, 2017
Overview:By Professor Masayuki Yoshida Statins have been the first choice option to prevent cardiovascular disease (CVD). However, because of insufficient efficacy in certain groups of high risk patients, such as familial hypercholesterolemia (FH), considerable interest exists in the search for... more
Association of treatment with losartan versus candesartan and mortality among patients with heart failure
May 02, 2012
Overview:Background Angiotensin receptor blockers (ARBs) are considered first line drugs for the treatment of chronic heart failure in most international committee guidelines. This recommendation is based in the result of several large randomized trials showing clear benefits, which include an... more